PRMT5抑制驱动套细胞淋巴瘤对BCL-2抑制联合治疗的治疗脆弱性
套细胞淋巴瘤(MCL)预后差且靶向治疗后进展者生存仅3至8个月。PRMT5在MCL中过表达并促进生长存活,其抑制降低AKT信号、促使FOXO1核转位并调控转录活性,BAX被鉴定为FOXO1直接转录靶点。在9株MCL细胞系中PRT382与venetoclax联合显示Loewe协同,在2个患者来源异种移植模型中联合治疗显示生存获益(P ≤ .0001,P ≤ .0001)。
要点
- PRMT5在MCL中过表达并促进生长与存活,抑制PRMT5在MCL细胞系和临床前小鼠模型中产生抗肿瘤活性。
- PRMT5抑制降低促存活AKT信号活性,导致FOXO1核转位并调控其转录活性。
- BAX为FOXO1直接转录靶点,在PRT382与venetoclax的协同中起关键作用。
核心结论
- 结果为此前临床前数据提供机制依据,支持联合PRMT5抑制与venetoclax治疗MCL患者。
研究设计与样本
- 在9株MCL细胞系中进行单药与联合处理,并在多个MCL模型及2个患者来源异种移植模型中进行临床前体内评估。
主要发现
- PRMT5抑制降低促存活AKT信号活性,导致FOXO1核转位并调控其转录活性。
- 染色质免疫沉淀测序鉴定多个促凋亡BCL-2家族成员为FOXO1结合基因组位点。
- BAX被鉴定为FOXO1直接转录靶点,并在PRT382与venetoclax的协同中起关键作用。
- Loewe协同评分显示在大多数受试MCL细胞系中具有显著协同水平。
- 联合venetoclax/PRT382治疗在2个患者来源异种移植模型中显示生存获益(P ≤ .0001,P ≤ .0001)。
关键数值与推荐
- MCL占每年诊断的非霍奇金淋巴瘤比例最高达6%。
- MCL患者平均总生存期为5年,靶向药物治疗进展后多数患者生存仅3至8个月。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is an incurable B-cell malignancy that comprises up to 6% of non-Hodgkin lymphomas diagnosed annually and is associated with a poor prognosis. The average overall survival of patients with MCL is 5 years, and for most patients who progress on targeted agents, survival remains at a dismal 3 to 8 months. There is a major unmet need to identify new therapeutic approaches that are well tolerated to improve treatment outcomes and quality of life. The protein arginine methyltransferase 5 (PRMT5) enzyme is overexpressed in MCL and promotes growth and survival. Inhibition of PRMT5 drives antitumor activity in MCL cell lines and preclinical murine models. PRMT5 inhibition reduced the activity of prosurvival AKT signaling, which led to the nuclear translocation of FOXO1 and modulation of its transcriptional activity. Chromatin immunoprecipitation and sequencing identified multiple proapoptotic BCL-2 family members as FOXO1-bound genomic loci. We identified BAX as a direct transcriptional target of FOXO1 and demonstrated its critical role in the synergy observed between the selective PRMT5 inhibitor, PRT382, and the BCL-2 inhibitor, venetoclax. Single-agent and combination treatments were performed in 9 MCL lines. Loewe synergy scores showed significant levels of synergy in most MCL lines tested. Preclinical, in vivo evaluation of this strategy in multiple MCL models showed therapeutic synergy with combination venetoclax/PRT382 treatment with an increased survival advantage in 2 patient-derived xenograft models (P ≤ .0001, P ≤ .0001). Our results provide mechanistic rationale for the combination of PRMT5 inhibition and venetoclax to treat patients with MCL.
引用
- Brown-Burke F, Hwang I, Sloan S, et al. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma. Blood Adv. 2023. PMID: 37327122. doi:10.1182/bloodadvances.2023009906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。